Vertex will buy Alpine Immune Sciences for $4.9B in another big Seattle biotech deal

Alpine Immune Sciences CEO Mitchell Gold in 2017. (AIS Photo)Boston-based biotech company Vertex Pharmaceuticals agreed to acquire Seattle-based Alpine Immune Sciences for $65 per share, totaling about $4.9 billion in cash, a 38% premium over Alpine’s closing price on Wednesday afternoon.The premium would have been higher, around 67%, based on Alpine’s closing price on Tuesday. However, the company’s stock jumped 21% in regular trading Wednesday after Bloomberg News reported it was considering a sale.Alpine ...